BioTechGrid – Page 2344

Pyxis Oncology shelves antibody to focus on sole clinical asset, an ADC licensed from Pfizer

December 19, 2024

Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results…

Biotechnology

Oncology biotech Epitopea licenses Genevant nucleic acid delivery tech for up to $123M

December 19, 2024

To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery specialist Genevant Sciences…

Biotechnology

Chutes & Ladders—FDA’s principal deputy to depart agency

December 19, 2024

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please…

Biotechnology

Omeros antibody improves overall survival by 68% in rare condition, new analysis finds

December 19, 2024

Omeros is putting up its monoclonal antibody up for FDA approval—again. This time, the resubmission will be based on a…

Biotechnology

Merck’s HIV combo treatment meets the bar for viral suppression in pair of phase 3 studies

December 19, 2024

After hitting the mark in a phase 2 of its investigational islatravir paired with Gilead’s lenacapivir, Merck & Co.'s islatravir…

Biotechnology

VC firm pens $608M biobucks deal to redirect NGM’s MASH drug to rare disease

December 19, 2024

KdT Ventures has signed off on a $608 million biobucks deal for NGM Biopharmaceuticals’ phase 2-ready metabolic-dysfunction associated steatohepatitis (MASH)…

Genetics

Scinai Immunotherapeutics Establishes U.S. CDMO Subsidiary

December 19, 2024

Scinai Immunotherapeutics, which focuses on developing inflammation and immunology biological products and providing CDMO services through its Scinai Bioservices business…

Biotechnology

Regeneron anticoagulant bests enoxaparin, matches Eliquis in phase 2 trial

December 19, 2024

A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial,…

Biotechnology

Vertex’s pain trial hits endpoint but sinks stock as placebo comparison spooks investors

December 19, 2024

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the near-approval…

Medical Technology

ElectroCore to buy NeuroMetrix and its Quell fibromyalgia wearable stimulator

December 19, 2024

Nerve stimulation company electroCore has signed an agreement to acquire NeuroMetrix and its Quell wearable device aimed at fibromyalgia and…

Malaria Parasite Membrane Enzymes Emerge as Promising New Drug Targets

Staphylococcal Protein Reprograms Liver Tumor Macrophages to Boost Immunotherapy

Hidden Microbes Inside Mung Bean Show Striking Stress Tolerance and Fungal-Fighting Power

Noisy Gates Put Gate Teleportation to the Test

Prenatal BPA Exposure Rewires the Cerebellum Differently in Male and Female Rat Offspring

Locked and Loaded: Structural Studies Reveal How the SCREW Peptide Engages Its NUT Receptor

Exploring the Future of Healthcare with Panos Karelis

Exploring the Future of Healthcare with Gordon Wishart, Check4Cancer

Exploring the Future of Healthcare with Noam Shomron, Tel Aviv University

Exploring the Future of Healthcare with Raul Villamarin Rodriguez, Woxsen University

Pyxis Oncology shelves antibody to focus on sole clinical asset, an ADC licensed from Pfizer

Oncology biotech Epitopea licenses Genevant nucleic acid delivery tech for up to $123M

Chutes & Ladders—FDA’s principal deputy to depart agency

Omeros antibody improves overall survival by 68% in rare condition, new analysis finds

Merck’s HIV combo treatment meets the bar for viral suppression in pair of phase 3 studies

VC firm pens $608M biobucks deal to redirect NGM’s MASH drug to rare disease

Scinai Immunotherapeutics Establishes U.S. CDMO Subsidiary

Regeneron anticoagulant bests enoxaparin, matches Eliquis in phase 2 trial

Vertex’s pain trial hits endpoint but sinks stock as placebo comparison spooks investors

ElectroCore to buy NeuroMetrix and its Quell fibromyalgia wearable stimulator

Siemens Healthineers and Novo team up on fatty liver disease awareness, testing

Cordis’ sirolimus drug-coated balloon earns FDA approval as a breakthrough device

Anaconda Biomed snares $56M in funding for endovascular tech

Medtronic earns FDA clearance for LigaSure use with its Hugo robotic system